Cole B J, Bostrom M P, Pritchard T L, Sumner D R, Tomin E, Lane J M, Weiland A J
Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, USA.
Clin Orthop Relat Res. 1997 Dec(345):219-28.
The ability of recombinant human bone morphogenetic protein 2 to remain osteoinductive and stimulate appositional bone formation on a porous coated implant was tested in a rat quadriceps muscle pouch. Implants with or without hydroxyapatite were used to compare the effects on bone formation of two different does (23 micrograms or 46 micrograms) of recombinant human bone morphogenetic protein 2 against controls as evidenced by contact radiography, histologic examination, and backscatter scanning electron microscopic analysis. Cylindrical plasma sprayed porous titanium implants were placed bilaterally within a muscle pouch surgically created in 48 Lewis rats. Implants treated with recombinant human bone morphogenetic protein 2 formed significantly more bone than did control implants independent of the dose or presence of hydroxyapatite. In all implants with bone formation, osteoinduction via endochondral ossification began within 7 days. By 21 days, cartilage largely was replaced by bone and marrow. The results of this ectopic, nonweightbearing in vivo assay suggest that recombinant human bone morphogenetic protein 2 remains biologically active after application to a titanium implant and may be used to enhance appositional bone formation by direct application to the implant surface.
在大鼠股四头肌肌袋中测试了重组人骨形态发生蛋白2在多孔涂层植入物上保持骨诱导活性并刺激贴壁骨形成的能力。使用有或没有羟基磷灰石的植入物，通过接触放射照相、组织学检查和背散射扫描电子显微镜分析，比较两种不同剂量（23微克或46微克）的重组人骨形态发生蛋白2对骨形成的影响与对照组。将圆柱形等离子喷涂多孔钛植入物双侧放置在48只Lewis大鼠手术创建的肌袋内。用重组人骨形态发生蛋白2处理的植入物比对照植入物形成的骨显著更多，与剂量或羟基磷灰石的存在无关。在所有有骨形成的植入物中，通过软骨内成骨的骨诱导在7天内开始。到21天时，软骨大部分被骨和骨髓取代。这种异位、非负重体内试验的结果表明，重组人骨形态发生蛋白2应用于钛植入物后仍保持生物活性，并且可以通过直接应用于植入物表面来增强贴壁骨形成。
